Engineered immune cells take on tough childhood cancers
NCT ID NCT06064903
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new treatment called CD7-CART01 for children whose T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma has come back or not responded to standard therapy. The treatment uses the child's own immune cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD7. The trial will first find the safest dose and then check how well it works at shrinking the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD7-CART01 (a type of CAR T-cell therapy made from the patient's own immune cells, engineered to target CD7 on cancer cells)
What this could lead to
If it works, this could offer a new treatment option for children with hard-to-treat T-cell leukemia or lymphoma, potentially leading to remission.
What could go wrong
This is an early-phase trial with only 26 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome or nervous system problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LYMPHOBLASTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ospedale Pediatrico Bambino Gesù
RECRUITINGRome, Rome, 00165, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact